Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
N Engl J Med. 2012 Jun 28; 366(26):2443-54
Jean Pierre Droz and Helen Boyle
18 Jul 2012
|
New Finding, Novel Drug Target
This article is an interesting phase I trial of a novel T-cell modulating antibody, anti-programmed-death 1 (anti-PD-1). The study gives interesting results (responses and disease stabilization) in patients with various primaries.
The PD-1 inhibitory receptor is expressed by T cells during long-term antigen exposure and results...
INDIVIDUAL SUBSCRIPTIONS
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.
Subscribe for $9.95/monthINSTITUTIONAL SUBSCRIPTIONS
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.
Recommend to your LibrarianIf you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.
Request an Institutional Trialyour institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.
If you think you should be able to access this content, please contact us.